Market Access & Reimbursement Strategy

Market access and reimbursement strategy connects what you prove for FDA approval with what payers and health technology assessment bodies need to support coverage and payment. Approval alone does not guarantee uptake. Endpoints, comparators, real-world evidence plans, and labeling language all influence how value is judged after launch, and late surprises here are expensive to fix once Phase 3 is locked and promotional claims must track the label.

Viltis helps life sciences teams bring access thinking into development earlier, without pretending regulatory strategy and payer strategy are the same workstream. We support alignment between clinical development, medical affairs, HEOR, and regulatory so evidence generation serves both agency review and downstream access conversations. That can include indication sequencing, outcomes of interest to payers, and how labeling claims will be supported in promotional and medical communications once OPDP rules apply.

Our consultants do not set prices or negotiate contracts for you. We help you frame evidence narratives, identify gaps relative to HTA and payer expectations, and coordinate with your commercial partners on materials that stay truthful to approved labeling and available data. When development choices would close a reimbursement door, we surface that risk while protocols and statistical analysis plans can still change.

Access work fails when it lives only in commercial decks after Phase 3. Embedding access questions into regulatory planning meetings keeps clinical endpoints and labeling concepts from drifting away from what payers will accept as meaningful differentiation versus standard of care. We also help teams pressure-test whether a proposed primary endpoint will read as clinically meaningful to payers even if it is acceptable to FDA, and what supportive analyses should be planned before database lock rather than invented afterward.

Market access strategy work often includes

• Early mapping of regulatory endpoints to access-relevant outcomes

Evidence gap assessments for U.S. and selected ex-U.S. markets

Coordination of RWE and observational plans with regulatory use

Labeling and claims implications for reimbursement messaging

Cross-functional workshops with clinical, HEOR, and commercial

Support for value dossiers and payer-facing evidence summaries

Scenario planning for indication expansion and line extensions

Access outcomes improve when regulatory and commercial teams share one evidence map. Viltis helps you build that map early enough to change study design, not only slide decks after approval day.